Hepatera Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 1
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2.08M
Latest Deal Amount
  • Investors
  • 4

Hepatera General Information

Description

Developer of drugs intended to be used for the prevention and treatment of liver diseases. The company's innovative drugs develop Myrcludex B which is directed to the treatment of chronic viral hepatitis B and D, enabling individuals to avail of enhanced drugs for better healthcare outcomes.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 12/19, Building 1, Verkhnyaya
  • Radishchevskaya street
  • Moscow, 119240
  • Russia
+7 8 (000) 000-00-00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Hepatera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 13-Jan-2016 $2.08M Completed Generating Revenue
1. Early Stage VC 20-Mar-2012 Completed Generating Revenue
To view Hepatera’s complete valuation and funding history, request access »

Hepatera Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hepatera Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Skolkovo Foundation Limited Partner 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
JibJigger R Other Minority 000 0000 000000 0
Maxwell Biotech Group Venture Capital Minority 000 0000 000000 0
To view Hepatera’s complete investors history, request access »